Dr. Mingshe Zhu Joins ChemPartner As Senior Fellow of DMPK

Appointment of Dr. Mingshe Zhu

ChemPartner, a global leader in drug discovery and development services, today announced the appointment of Dr. Mingshe Zhu as the Senior Fellow of the DMPK department. Dr. Mingshe Zhu will be responsible for:

  • Supporting the expansion of overseas DMPK business
  • Providing professional technical support to our clients
  • Expanded professional technical training of ChemPartner’s DMPK department

Dr. Zhu has over twenty years of experience in drug discovery and development. Dr. Zhu received his PhD in Chemical Toxicology from the University of Albany and was a Postdoctoral Fellow in Drug Metabolism at the School of Pharmacy at the University of Washington. He has been responsible for dozens of DMPK projects to support lead optimization, clinical candidate evaluation, in vitro DDI, in vivo ADME studies, and regulatory submissions of drug candidates. He previously served in roles as the CSO and Principal Consultant at XenoFinder Co., Ltd., Visiting Professor at Xiamen University exploring DMPK methodologies in the development of new traditional Chinese medicines, Scientific Advisor for WuXi AppTec DMPK Nanjing Site, and Principal Scientist in the Department of Biotransformations at Bristol-Myers Squibb.

Dr. Zhu has published over 100 research papers and reviews and has co-edited two books: Drug Metabolism in Drug Design and Development: Basic Concept and Practice and Mass Spectrometry in Drug Metabolism and Disposition: Basic Principles and Applications. Recently, his research interests have been expanded to unconventional drug modalities, such as ADC, PDC, PROTACs, cyclic peptide drugs, herbal medicines, covalent drugs, and stable isotope-labeled drugs. We believe he will bring new vitality and growth momentum to the company.

Dr. Zhu will be presenting a Two-Day Short Course on June 1-2, 2024 entitled “DMPK: Experimentation and Data Interpretation” at the upcoming ASMS Conference on Mass Spectrometry and Allied Topics Annual Meeting alongside Dr. Naidong Weng, Senior Director and Head of LC-MS Bioanalysis and Biomarkers within Bioanalysis, Biomarkers, and Immunogenicity (BIB) at GSK.


New Management Structure of the DMPK Department

The DMPK department will be co-managed by Dr. Xinxin Yang and Dr. Xinyan Lu. Their main responsibilities are as follows:

  • Xinxin Yang: In vivo pharmacokinetics, early toxicology, and bioanalysis
  • Xinyan Lu: In vitro metabolism and early toxicology

We believe that under the joint efforts of Dr. Yang and Dr. Lu, the DMPK department at ChemPartner will continue to provide high-quality services to our clients.

We appreciate your continued support and trust of ChemPartner. We look forward to continuing to work with you under the leadership of the new management team. Click here to learn more about ChemPartner’s DMPK and exploratory toxicology services and experience. If you have any questions or need further information, reach out to our scientific teams today.

Read More…

ChemPartner Unveils Highly Anticipated Biology Database

Newly-launched database offers easier access to diverse tumor models and unveils the path to pharmaceutical breakthroughs   ChemPartner, a global leader in drug discovery and development services, today announced the launch of its long-awaited Biology Database....


1F & 3F, Block A
2829 JinKe Road
Zhangjiang Hi-Tech Park
PuDong New Area
Shanghai China, 201203


Contact Us

China: +86 21 5132 0088
US: +1 650 419 9974
Europe: +45 4586 9000


Share This